Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
En este foro anual de pacientes en vivo, los principales oncólogos torácicos de todo el mundo discuten temas relevantes para los objetivos del cáncer de pulmón, así como mutaciones raras.
Este seminario web virtual en vivo es una oportunidad para que los pacientes con cáncer de pulmón y los cuidadores escuchen a los expertos y participen en sesiones de preguntas y respuestas virtuales en vivo. El foro ofrece paneles de discusión y sesiones de preguntas y respuestas en vivo. Este evento es gratuito, pero el registro es obligatorio y limitado. Para más información visita la AGENDA completa. La biografía de la facultad estará disponible pronto.
Presentado por:
Facultad REGÍSTRESE AQUÍ AHORA
AGENDA del Foro de Terapias Dirigidas en Pacientes con Cáncer de Pulmón 2023
Horarios enumerados en EasternTime ***Sujeto a cambios***
Presidente del evento / Event Chair Luis Raez, MD
|
|
|
9:00 AM
|
Bienvendia y Palabras de Apertura / Welcome and Opening Remarks Event Chair: Dr. Luis Raez
|
|
9:10 AM
9:55 AM
10:25 AM
10:55 AM
11:25 AM
|
Discusion del Panel: Presentaciones de Casos con Mutaciones EGFR y Resistencia Panel Discussion: Presentation of Cases with EGFR Mutation and Resistance Cases/moderator: Dr. Fernando Diaz, Panel: Alberto Chiappori, Luis Corrales, Estelamari Rodriguez
Desafíos en el Diagnóstico Molecular y el Papel Que Juegan las Biopsias Líquidas Challenges in Molecular Diagnostics and the Role of Liquid Biopsies Dr. Luis Raez
Terapias Dirigidas para Tumores KRAS Targeted Therapies for KRAS+ Tumors Dr. Luis Corrales
Terapias Dirigidas Para NSCLC Temprana Targeted Therapies for Early NSCLC Dr. Estelamari Rodriguez
Panel y Q&A Panel and Q&A Dr. Luis Raez (moderator), Diaz, Corrales, Chiappori, Rodriguez |
|
11:45 AM
|
Mensaje de Agradecimiento y Despedida / Thank you and Closing Event Chair: Dr. Luis Raez
|

Please feel free to offer comments and raise questions in our
discussion forums.
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)
There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...
Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.
The...
Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...
Hi Stan! So good to hear from you. I'm sorry for the late response. I too have been out of town with family and missed your post, probably because I was...
It is so good to hear from you! And I am so happy to hear that your holidays have been good and that you are doing well. It sounds like your...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components: